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Background: Copy number variations (CNVs) can contribute to genetic variation among individuals and/or have a
significant influence in causing diseases. Many studies consider new CNVs’ effects on protein family evolution
giving rise to gene duplicates or losses. “Unsuccessful” duplicates that remain in the genome as pseudogenes often
exhibit functional roles. So, changes in gene and pseudogene number may contribute to development or act as
susceptibility alleles of diseases.
Case presentation: We report a de novo heterozygous 271 Kb microdeletion at 8q21.2 region which includes the
family of REXO1L genes and pseudogenes in a young man affected by global development delay, progeroid signs,
and gastrointestinal anomalies. Molecular and cellular analysis showed that the REXO1L1 gene hemizygosity in a
patient’s fibroblasts induces genetic instability and increased apoptosis after treatment with different DNA
damage-induced agents.
Conclusions: The present results support the hypothesis that low copy gene number within REXO1L1 cluster could
play a significant role in this complex clinical and cellular phenotype.
Keywords: 8q21.2 microdeletion, REXO1L1 gene, aCGH, CNV, Facial dysmorphisms, Inflammation and apoptosis of
gastrointestinal mucosaBackground
Microarray-based comparative genomic hybridization
(aCGH) is the current molecular technique used to diag-
nose submicroscopic deletions or duplications with higher
resolution than classical cytogenetic banding in a single
assay. It has applied to clinical diagnostics of patients with
dysmorphic features, developmental delay, and/or idio-
pathic mental retardation and to delineate alterations that
could be used to classify different subtypes of human
tumours [1,2].* Correspondence: d.apice@med.uniroma2.it
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unless otherwise stated.Moreover, the application of array CGH has led to the
detection of large numbers of structural genomic rear-
rangements known as copy number variations (CNVs) in
patients and in the normal population. CNVs can repre-
sent benign polymorphic variants, driving gene and gen-
ome evolution. The current challenge is the interpretation
of the CNVs clinical significance in sporadic traits and in
causing susceptibility to complex diseases [3,4]. In fact,
the number of microdeletion and microduplication syn-
dromes (MMSs) and the phenotypic consequences is con-
tinuously increasing [5]. Here, we describe a patient with
malabsorption syndrome, growth retardation, dysmorphic
features and dyspraxia associated with enhanced epithelial
cells apoptosis in the gastrointestinal tract. Array-CGHl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mapping in 8q21.2 band containing the REXO1L1 gene
and 3 REXO1L2P pseudogenes. We demonstrate that the
observed chromosome deletion could be causative of the
clinical and cellular phenotype observed in the patient.
Case presentation
Clinical report
The patient was born preterm by vaginal delivery, show-
ing 2.900 Kg weight at birth. He underwent surgery to
correct a cleft of the soft palate, while the incomplete
spina bifida, diagnosed when he was a newborn, not
required surgical treatment. At age 4, he had a diagnosis
of dyspraxia, requiring regular Psichiatry Day Hospital
admissions till 18 years old. At age 17, growth retard-
ation and delayed puberty were diagnosed. An extensive
paediatric work up revealed a short stature, mildly
increased Body Mass Index (BMI), dyspraxia and osteo-
porosis (reduced age-related bone mass: T score −2.56,
Z score = −2.31). At age 22, he referred to our gastro-
intestinal unit for chronic diarrhoea with weight loss not
related with reduced food intake, and no responsiveness
to anti-diarrhoeal drugs. At the time of admission, the
patient appeared in poor conditions and older than his
age. Physical examination revealed several dysmorphic
features, including large palpebral fissures with long eye-
lashes, arched eyebrows, large ears, micrognathia, hypo-
dontia, few and rare hair, together with cleft palate and
velum pendulum bifidum. Routine blood chemistry de-
tected reduced serum levels of total IgA (35 mg/dL; n.v.
70–400) and IgE (0 UI/ml; n.v. 20–100 UI/ml). A low
grade hypoprotidemia (6.4 gr/dL) and hyperbilirubine-
mia (total 1.34 mg/dl, direct 0.39 mg/dL) were observed.
The mean daily stools weight (2 determinations in
24 hours) was 1117 gr/24 hr, with steatorrhoea (8 gr/24 hr)
and a positive occult faecal blood test.
Esophagogastroduodenoscopy (EGDS) detected a nor-
mal macroscopical aspect of the Kerkring folds in the
second portion of the duodenum, with multiple whitish
spots compatible, but not specific, for lymphangiectasia
[6]. However, focal areas with partial atrophy of the villi
and an increased inflammatory infiltrate in the lamina
propria were observed. Ileocolonoscopy showed multiple
areas of brownish “alligator skin” appearance of the in-
testinal mucosa were observed, associated with dis-
appearance of the vascular pattern and tubular aspect of
the colon (Figure 1A). In the distal ileum, histological
analysis showed an increased inflammatory infiltrate with
occasional apoptotic bodies within the crypts (Figure 1B).
Microscopic analysis of biopsy samples of colon detected
an increased infiltration of plasmacells and eosinophils.
Diffuse mucous depletion and apoptotic bodies within the
crypts and at the basal portion of the glands were also ob-
served. These findings were more relevant in the rectum,ascending and descending colon, when compared to the
ileo-cecal valve. Mucosal atrophy was also observed. After
treatment with probiotics and loperamide, partial and
temporary reduction of the daily bowel movements, asso-
ciated with no weight gain, have been observed.
Due to the persistence of diarrhoea, a gluten-free diet
was started, followed by temporary resolution of this
symptom (1 bowel movement every 2 days). In a succes-
sive reassessment of the disease, the patient appeared in
discrete general conditions. A new EGDS showed a
brownish mucosa covering the fundus, corpus and an-
trum, with no active erosions or ulcers (Figure 1C). The
second portion of the duodenum showed multiple whitish
spots, comparable to those reported in the previous EGDS
(Figure 1D). Biopsy taken from the angulus, antrum, cor-
pus and fundus showed a mild inflammatory infiltrate in
the lamina propria, occasional lymphoid aggregates and
limited aspects of foveolar hyperplasia. More importantly,
focal apoptotic glandular necrosis was observed in the
fundic mucosa. Histology of the second portion of the
duodenum detected aspecific dysmorphism of the villi,
mild increase of the inflammatory infiltrate in the lam-
ina propria, focal mucous depletion and regenerative
dysplasia.
In order to search for superficial small bowel lesions, a
small bowel capsule endoscopy (SBCE) confirmed the
findings detected by EGDS, including the presence of
multiple and diffuse whitish spots extending from the
second portion of the duodenum to the proximal je-
junum (Figure 1E) [7]. SBCE also showed in the jejunum
and ileum multiple subcentrimetric nodular areas covered
by normal mucosa, compatible with nodular lymphoid
hyperplasia (Figure 1F). Routine blood chemistry during
hospitalization detected a mild hypocholesterolemia (HDL)
(31 mg/dl; n.v. 35–60) and hypoprotidemia (6.2 g/dl; n.v.
6.6-8.7) with normal serum albumin (3.9 g/dl) and lower
levels of β1 (0.33 g/dl; n.v. 0.4-0.9) and β2 globulins
(0.25-0.7 g/dl; n.v. 0.25-0.7).
Methods
Research carried out on patient’s fibroblasts was performed
in compliance with the Helsinki Declaration (http://www.
wma.net/en/30publications/10policies/b3/index.html) and
received the approval of the ethics committee of Policlinico
Tor Vergata (153/08).
Cytogenetic and molecular studies
Comparative genomic hybridisation (CGH) analysis was
performed on genomic DNA (gDNA) using the Spectral-
Chip™2600 (Spectral Genomics Inc., Houston, TX). Test
and normal reference DNA were processed according to
manufacturers’ instructions. Slides were scanned on a
GenePix 4000B scanner (Axon Instruments, Union City,
CA). The acquired microarray images were analyzed by
Figure 1 Ileocolonoscopy and esophagogastroduodenoscopy. (A) Presence of multiple areas of brownish “alligator skin” appearance of the
intestinal mucosa, associated with disappearance of the vascular pattern and tubular aspect of the colon. (B) Histological analysis of a biopsy
specimen taken from the distal ileum during ileocolonoscopy showed several apoptotic cells in along the epithelial cells lining the crypts
(arrows). (C) EGDS of the gastric antrum showed multiple areas of brownish (“alligator skin”) appearance of the mucosa, in the absence of active
erosions or ulcers. (D) The second portion of the duodenum showed multiple whitish spots compatible but not specific for lymphangiectasia.
(E) SBCE showed the presence of multiple whitish spots in the second part of the duodenum (confirming findings at EGDS) extending to the
proximal jejunum. (F) SBCE showed multiple subcentimetric nodular areas covered by normal mucosa in the jejunum and ileum, compatible with
nodular lymphoid hyperplasia.
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calculates hybridization ratio for each clone in the two ex-
periments and generates a profile for each chromosome.
Fluorescence in situ hybridisation (FISH) analysis was per-
formed using RP11-96G1 (hg18 chr:86,851,750-86,955,528),
RP11-133G2 (hg18 chr8:86,558,072-86,717,112), RP11-179B4 (hg18 chr8:86,988,241-87,124,169) BAC clones
and centromeric probe of chromosome 8 on metaphase
spreads obtained from peripheral blood of our patient
and his parents using standard procedures.
Gene copy number variation analysis was performed on
gDNAs extracted by sixty healthy blood donors, proband
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We used, as calibrator, the REXO1L1 (FAM) gene cloned
into pCMV6-XL6 (OriGene Technologies, Inc., Rockville,
USA), and as reference gene the RNaseP (VIC) gene
(Applied Biosystems, Foster City, CA), that it is known to
be present in the human haploid genome in single copy.
PCR was carried out using 10 ng of gDNA, 12.5 μl of
Master mix (Applied Biosystems) and 1.25 μl of REXO1L1
and RNaseP commercial probes together or separately.
The thermal cycling conditions were: 2′ at 50°C, 10′ at
95°C and for 40 cycles 15″ at 95°C and 1′at 60°C. PCR
was performed in a 96-well optical plate (ABgene) using
the ABI7000 Real Time PCR System (Applied Biosystems).
All DNA samples were amplified in triplicate. Two
standard curves, with a known copy number of calibra-
tor and reference gene, were prepared in duplicate. A
no-template control (negative control) was also included
in each assay.
Real-time efficiencies were calculated by means of
standard calibration curves and the initial concentration
of the sample was calculated by using the comparative
ΔΔCt method as the gene copy number was given by
the formula 2−(ΔΔCt+/−SD), where ΔΔCt = (Ct RNaseP
calibrator − Ct REXO1L1 calibrator) − (Ct RNaseP sam-
ple −Ct REXO1L1 sample). The Ct value was deter-
mined by using the instrument’s software and adjusted
manually as necessary.
REXO1L1 gene expression was performed on total RNA
isolated from peripheral lymphocyte, fibroblasts, and can-
cer cell lines by TRIzol® method (Invitrogen Ltd, Paisley,
UK). Given the monoexonic structure of REXO1L1 tran-
script, we incubate 3 μg of RNA with 2 U of DNase I
enzyme (Ambion) at 37°C for 30 min. Then, the RNA was
reverse-transcribed to cDNA using the High-Capacity
cDNA Archive Kit (Applied Biosystems). The REXO1L1
gene was amplified using specific primers (Fw AGCT
CAAGGAGAACGGCTACC, Rw TTGTGGCCGTCCTG
GCTGTCC). Obtained amplicon was checked by sequen-
cing analysis, to make sure that only the specific product
was amplified.
Four micrograms of total RNA, isolated from patient’s
fibroblasts, were analyzed using GEArray S Series Human
Apoptosis and Cell Cycle Gene Array HS-603 (SuperArray
Bioscience Corporation), containing 96 key apoptosis genes,
96 key cell cycle regulation genes, 75 stress & toxicity
genes, negative controls (pUC18 DNA and blanks), and
putative housekeeping genes (β-actin, GAPDH).
Cellular analysis
Human fibroblast HFFF2 cell line and patient’s fibroblasts
were cultured in DMEM-F12 medium supplemented with
15% foetal calf serum (FCS) and 1% L-glutamine. The
HeLa and the HEK293 cell lines were growth in DMEM
medium supplemented with 10% FCS. All culture mediacontains antibiotics. All the cell cultures are growth at
37°C under an atmosphere of 5% CO2.
For the radiation treatment, cells in exponential phase
of growth were exposed to X-rays delivered by a Gilardoni
MGL 300/6-D apparatus (Gilardoni, Mandello Lario, Italy),
operating at a dose rate of 0.53 Gy/min (250 kV, 6 mA,
Cu filter).
Micronuclei (MN) induction on HFFF2 and patient’s
fibroblasts was performed by treatment with either 4–
8 J/m2 of UV-C, or with 2–5 μM Hydroxyurea, or 25,
50 and 100 μM t Butil-hydroxiperoxide or 0.25, 0.5 and
1 Gy of X-rays, and exposition with cytocalasin B (3 μg/ml)
for 72 hrs. Cells were then fixed in situ by the gradual add-
ing of methanol:acetic acid (3:1), slides were air-dried and
stained with 3% Giemsa for 10 min. At least 500 binu-
cleate cells (BNC) were scored for MN induction for each
experimental point.
DNA double strand breaks (DSBs) repair measurements
were performed after treatment with 40 Gy and repair in-
cubation (0, 1, 2, 6, 24 hrs). Cells were harvested, embed-
ded in agarose plugs (Low Melting Gel Type VII, Biorad)
and lysed. PFGE was carried out with a Chef Mapper™
(Pulsed Field Electrophoresis System, Bio-Rad) in 0.8%
Certified Molecular Biology Agarose (Bio-Rad) and 0.5 X
TAE at 14°C. The run was performed first for 65 hrs at
1.5 V/cm using a 50–5000 sec switching time, then for
4 hrs at 6 V/cm using a 7–114 sec switch time block. Gels
were stained with ethidium bromide and photographed
with Fluor-S Imager (Bio-Rad) under UV transillumin-
ation. Densitometry was performed with Multi-Analyst
software (Bio-Rad). The amount of DNA entering the gel
was quantified.
Immunofluorescence analysis of γ-H2AX foci was
performed on normal and patient’s fibroblasts after irra-
diation with 1 Gy of X-rays and fixation after 0.5, 6 and
24 hrs in 2% paraformaldehyde. Slides were incubated
over night with 1 μg/ml γ-H2AX mouse monoclonal anti-
body (Upstate), and detected with an anti-mouse FITC-
conjugated antibody (Vector). Images were captured
using a Zeiss Axioplan 2 imaging epifluorescent microscope
equipped with a charge-coupled device camera (CCD cam-
era) and IAS2000 software. Quantitative analysis was car-
ried out by counting foci in at least 50 cells/experiments.
Apoptosis assay was performed on cells harvested after
48 hrs from X-irradiation, washed with cold phosphate-
buffered saline (PBS) and fixed with 70% ethanol. Fixed
cells were treated with 20 μg/ml RNase and finally DNA
was stained by addition of 50 μg/ml propidium iodide
solution for 30 min at 37°C. To determine the DNA con-
tent of each sample, 10.000 cells were analysed, using a
Galaxy Flow Cytometer (Dako). Percentages of cells in the
different phases of cell cycle and cells with hypodiploid
DNA content were established using the FloMax (Version
2.4b, Partec).
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Analysis of the ratio profiles obtained by array-CGH
showed a deletion of a single bacterial artificial chromo-
some (BAC) clone, RP11-96G1, mapping in 8q21.2 band
(Figure 2A). To validate the results of CGH-array, a
fluorescence in situ hybridization (FISH) analysis using
the same clone was carried out. A single signal on one
of the chromosomes 8 was detected in patient’s metaphase
(Figure 2B). The deletion at 8q21 was also detected by
qPCR. The patient’s genomic DNA contains half dose ofFigure 2 Microdeletion characterization. (A) For the array-CGH profile o
according to physical mapping position. The Y axis (blue and red) mark the
Black arrow showed microdeletion of a single clone (RP11-96G1) on 8q21.2
CGH results using FISH analysis with RP11-96G1 clone. White arrow shows
RP11-133G2 and RP11-179B4, overlapping partially the deleted clone, show
the deleted region in 8q21.2 cytogenetic band using the UCSC browser, inregion (data not shown). Both molecular techniques ruled
out the presence of deletion in both parents, indicating its
de novo origin. Then, the extension of the deleted region
was determined using flanking clones (RP11-133G2 and
RP11-179B4). FISH analysis with these probes showed
one signal on both chromosomes 8, therefore microde-
letion has been limited to RP11-96G1 clone, spanning
for 104–271 Kb (arr[hg18] 8q21.2(86,717,112x2,86,851,750-
86,955,528x1,86,988,241x2)) on 8q21.2 (Figure 2C-D). The
deleted region contains the REXO1L1 gene (NM_172239,f chromosome 8, clones are ordered on the X axis from pter to qter
normalized hybridization Cy5:Cy3 and Cy3:Cy5 ratios of the two arrays.
(ratio plot: 0.67 in both experiments). (B) Confirmation of array
the chromosome 8 containing the microdeletion. (C–D) FISH with
ed that microdeletion spreads out along ~150 Kb. (E) The panel shows
which the involved BAC clone and genes are displayed.
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previously called GOR) and 3 REXO1L2P pseudogenes
(REX1, RNA exonuclease 1 homolog (S. cerevisiae)-like 2)
(Figure 2E). The analysis of copy number variation by
qPCR revealed 8 copies of gene and pseudogenes in the
proband’s DNA. All analyzed sixty healthy subjects dis-
played a variable number between 16–24 copies of
REXO1L1 gene and pseudogenes per diploid genome
(data not shown).
We examined the expression of the REXO1L1 gene in
several well-known cell lines by RT-PCR. REXO1L1 gene
is expressed in several mammary and gastrointestinal can-
cer cells (Figure 3A). Moreover, the REXO1L1 gene pro-
duces an inducible mRNA, comparing the expression
level in HEK293 cell line treated with 5 Gy of X-rays and
harvested 30 min and 1 h later. A significant time-
dependent up-regulation of REXO1L1 gene was ob-
served in irradiated cells (Figure 3B).
To investigate the functional effect of REXO1L1 gene
hemizygosity, we performed microarray analysis on the
apoptosis and cell cycle regulation genes in patient’s
fibroblasts. We used the GEArray S Series Human
Apoptosis e Cell Cycle Gene Array HS-603, a filter array
containing 96 key apoptosis genes, 96 key cell cycle
regulation genes and 75 stress & toxicity genes. Consid-
ering only genes whose differential expression had a
threshold > ±2, we identified a total of 29 differentially
expressed genes (10.9%). A great number of these tran-
scripts are heat shock genes (44.8%). The remaining
group of altered genes are transcripts that take part in the
regulation of protein turn-over (13%), cell cycle division
(6.8%) and progression (3.4%), apoptosis (6.8%) (Figure 3C).
Cells were treated with DNA damaging agents
known to induce different kind of DNA lesions. No
differences were scored in the frequency of MNFigure 3 Gene expression results. (A) Relative expression of the REXO1L1
SW480, and SW620 = human colon cancer cell lines, MCF-7 and MCF12F =
the REXO1L1 gene measured by RT-PCR in HEK293T (Human Embryonic Kid
(C) Differentially expressed genes identified by microarray analysis in proba
which are involved.induced by treatment with either 4–8 J/m2 of UV-C
or with 2–5 μM Hydroxyurea. Contrastingly, fibro-
blasts established from the proband showed a higher
frequency of MN after exposure to either the oxidant
agent t-Butyl hydroperoxide or X-rays, indicating sensi-
tivity towards agents able to induce DNA-strand breaks
(Figure 4A).
To measure the DNA DSBs repair capability in cells
established from the proband, pulsed field gel electro-
phoresis (PFGE) analysis was performed. Cells were irra-
diated with 40 Gy and the fraction of activity released
(FAR) was measured 1, 2, 6 and 24 hrs after treatment.
Analysis of the time-course for DSBs rejoining showed
an overimposable kinetics of repair in both HFFF2
and patient’s cells (Figure 4B). In order to further cha-
racterize the repair capability of patient’s cells at biological
relevant doses, a more sensitive assay was used. The
number of phosphorylated H2AX (γ-H2AX) foci was
scored in cells treated with 1 Gy of X-rays and harvested
after 0.5, 6 and 24 hrs. Consistent with the PFGE results,
the mean number of foci detected in patient’s cells was
quantitatively similar to that scored in control cells
(Figure 4C).
Primary fibroblasts were synchronized into G0/G1
by serum starvation for 72 hrs, allowed to resume cell
proliferation in 15% FBS-containing medium, then
harvested and analysed by FACS for the presence of hypo-
diploid DNA contents, a measure of apoptosis. Interest-
ingly, patient’s fibroblasts showed a high percentage of
apoptotic cells compared to HFFF2 cells. In particular,
independently from the X-ray treatment, a percentage of
apoptotic cells comprised between the 42.3% and the
48.2% was observed in patient’s fibroblasts, whereas this
percentage was comprised between 11.1% and 14.3% in
HFFF2 cells (Figure 4D).gene measured in several cell lines by RT-PCR. CaCo-2, HCT116,
human breast cancer cell lines, M = marker. (B) Relative expression of
ney 293) cells after irradiation (5 Gy) as compared to untreated cells.
nd’s fibroblasts are grouped according to the biological process in
Figure 4 DNA damaging analysis. (A) MN frequency scored in binucleated cells. (B) Analysis of the DSBs rejoining capability of patient’s cells
by PFGE after 1, 2, 6 and 24 hrs from 40 Gy X-ray treatment. (C) The number of phosphorylated H2AX (γ-H2AX) foci scored in cells treated with
1 Gy of X-rays and harvested 0.5, 6 and 24 hs later. (D) Analysis of apoptotic cells in a patient’s fibroblasts compared to HFFF2 cells.
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We report on a 22-year-old patient, with malabsorption
syndrome and multiple anomalies including facial dys-
morphisms, growth retardation, and incomplete spina
bifida, dyspraxia and presence of apoptotic bodies and
lymphocytes in GI tract. The aCGH screening identified
a de novo 150 Kb deletion in the long arm of chromosome
8 in the 8q21.2 band. Searching for the genes contained
within the region of genomic imbalance, we found the
REXO1L1 gene and 3 REXO1L2P pseudogenes (Figure 2E).
Structural variants, jointly with single-nucleotide changes,
are thought to be the major contributors to genetic vari-
ation among individuals [8]. Although structural variants
in some genomic regions have no obvious phenotypic
consequence, others may have a significant influence in
causing diseases. To interpret the clinical significance of
our CNV, we used the Database of Genomic Variants
containing data on hundreds of healthy individuals and
publicly available databases listing pathologic chromo-
some aberrations [9,10]. The RP11-96G1 clone is reported
to be involved in CNVs in health subjects and patients. In
particular, Iafrate et al. report 9 control samples and 8
patients sharing gain/loss of genomic region covered by
our clone [11]. This region is also involved in other catalo-
gued duplications reported in the most part of structural
variation studies on control samples. Only two researches
specify the identified deletion in few individuals, while the
genome of a single individual presents an involving of
genomic region in inversion rearrangement. Often, the
low CNVs frequency and the use of a single platform and
technology to identify CNVs let researchers to misclassify
their clinical significance. The application of aCGH
technology has improved the detection of many sub-
microscopic chromosomal imbalances in children with
dysmorphism and developmental delay/mental retardation,
allowing for a specific diagnosis in patients previously
considered to have an idiopathic etiology [12-14]. More
recently it became clear that some of the alterations that
were at first considered benign CNVs, showed to be
enriched in affected population [15]. Gain/loss of genetic
segments involving REXO1L1 gene is absent from an in-
ternal database that include CNVs obtained during valid-
ation of our array CGH platform. Such validation studies
used DNAs from 100 healthy control individuals. More-
over, we found only an increase of REXO1L1 gene and
REXO1L2P pseudogenes copy number in healthy Italian
subjects by molecular techniques. On the other hand, the
investigated region on chromosome 8q21.2 is resulted part
of greater deletion (15 Mb at 8q21.11→q21.3) in syn-
dromic patients [16]. Then, the REXO1L1 gene has been
identified in a genomic gain in SKBR3 breast cancer cell
line [17]. Our deletion is unlikely to constitute an artefact.
The confirmation of the aCGH results by molecular tech-
niques, the absence of deletion in control samples, theoverlapping with characterized genome imbalances in af-
fected individuals, its de novo origin, all factors influencing
the risk assessment of a CNV, corroborated opinion that
our CNV is more likely to be pathogenetic in determining
patient phenotype [16]. However, the potential clinical
relevance of a CNV depends also on the number of genes
within the imbalanced region. Our CNV is gene poor, but
contains a high number of pseudogenes. Many studies
consider the CNVs’ effect on contribution to protein fam-
ily evolution [18]. After formation and subsequent fixation
following selection or random drift, CNVs may give
rise to gene duplicates or losses [19]. Many “unsuccessful”
duplicates remain in the genome as pseudogenes. Protein-
coding genes acting in metabolism and cellular physio-
logical processes, that is dosage-sensitive genes, and genes
putatively involved in environmental response appear sig-
nificantly enriched among pseudogenes [19]. The concept
of pseudogenes as “junk DNA” seems overcome. Pseu-
dogenes often exhibit functional roles, such as gene ex-
pression, gene regulation, generation of genetic (antibody,
antigenic, and other) diversity [20]. So, changes in gene
and pseudogene number may contribute to development
or act as susceptibility alleles of diseases [21-23]. In other
cases, ‘resurrection’ of duplicated pseudogenes can result
in an expressed protein [18]. Therefore, duplicated pseu-
dogenes can be considered to be a resurrectable reservoir
of diversity.
How does the deletion involving REXO1L1 gene/
REXO1L2P pseudogenes can influence the patient’s
phenotype? The human GOR gene (alternative REXO1L1
gene symbol) produces a 3′-5 exonuclease (exo) belonging
to DEDDh family, composed of RNase T, RNase D and
oligoribonuclease in prokaryotes, involved in 3′ ma-
turation of several small stable RNAs, or in recycling of
short oligonucleotide generated by other 3′ exo activities
[24-27]. In eukaryotes there are several different DEDD
superfamily 3′ exos involved in a wide range of activities
including RNA maturation, nuclear mRNA surveillance
and decay, and control of HBV and RNA virus infections
[28-35]. Although, it was initially proposed that oligoribo-
nuclease does not attack deoxyribonucleotides, it was
recently shown that it can degrade short DNA oligos [36].
Interestingly, this highlights a possible role for oligoribo-
nuclease in DNA repair, like its human counterpart
[37]. So, we speculate that variable REXO1L2P pseudo-
gene number in control population can be a protection
factor against viral infections. On the contrary, our pa-
tient carrying out low copy number of the REXO1L2P
pseudogenes could be more predisposed to contract
viral illness. In fact, we also observed expression changes
for a high number of heath shock genes codifying
proteins (HSPs) induced by stress factors and playing
a role as molecular chaperones and in antigen presen-
tation [38].
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DNA damage response in patient’s cells have been inves-
tigated. First, fibroblasts established from the patient
showed a higher frequency of MN after exposure to both
the oxidant and ionizing radiation (IR) agents, indicating
sensitivity towards agents able to induce DSBs, the most
important lesions leading to chromosomal aberrations
[39]. Nevertheless, a complete recovery of unrejoined
DSBs after 24hs from IR in proband fibroblasts com-
pared to control cell line and the same mean number of
phosphorylated H2AX (γ-H2AX) foci detected in the
patient’s cells and in control cells indicated the ability of
affected fibroblasts to repair DNA damage. Both gen-
omic instability and increased apoptosis in patient’s cells
could be explained by the role of REXO1L1 gene prod-
uct. However, the exoribonuclease function of REXO1L1
protein and its involvement in the mechanism of DNA
repair and apoptosis remain to be demonstrated in fur-
ther experiments.Conclusions
In conclusion, the reported study shows a genomic dis-
order caused by new structural change at 8q21.2 region.
The consequent gene imbalance is absent as polymorphic
variants in the general population and behaves as disease
determinant of the patient dysmorphic phenotype. We
further illustrated that affected fibroblasts share genomic
instability and alteration of mRNA expression profile.
Consequently, our results support the hypothesis that low
copy gene number within REXO1L1 cluster identified in
the patient could play a significant role in his clinical and
cellular phenotype. If this genomic imbalance is associated
to a major susceptibility to viral infections, that could ex-
plain both the high apoptosis level and the high number
of differentially expressed heath shock genes, is currently
under investigation.
Our contention is the identification of low size chromo-
somal aberrations by standard karyotyping methods is dif-
ficult contributing to its rarity in the recognition of new
microdeletion syndromes. However, the use of aCGH
screening in dysmorphic patients with global developmen-
tal delay, progeroid signs and gastrointestinal anomalies
should increase the recognition of individuals carrying this
novel deletion.Consent
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